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Entecavir (ETV) is one of the most potent agents for the treatment of the hepatitis B
viral infection. The drug is principally eliminated by the kidney. The goal of this study
was to investigate the potential of ETV to interact in vitro with the renal SLC transporters
hOAT1, hOCT2, hCNT2 and hCNT3. Potential drug–drug interactions of ETV at the renal
transporters with antiviral drugs known to be excreted by the kidney (adefovir, tenofovir,
cidofovir) as well as transporter-dependent cytotoxicity were also examined. Interactions
with the selected transporters along with cytotoxicity were studied in several transiently
transfected cellular models using specific substrates and inhibitors. ETV was found to be
both a substrate and inhibitor of hOAT1 (IC50 = 175.3 μM), hCNT2 (IC50 = 241.9 μM)
and hCNT3 (IC50 = 278.4 μM) transporters, although it interacted with the transporters
with relatively low affinities. ETV inhibited the cellular uptake of adefovir, tenofovir, and
cidofovir by hOAT1; however, effective inhibition was shown at ETV concentrations
exceeding therapeutic levels. In comparison with adefovir, tenofovir, and cidofovir, ETV
displayed no transporter-mediated cytotoxicity in cells transfected with hOAT1, hCNT2,
and hCNT3. No significant interaction of ETV with hOCT2 was detected. The study
demonstrates interactions of ETV with several human renal transporters. For the first
time, an interaction of ETV with the hCNTs was proved. We show that the potency of
ETV to cause nephrotoxicity and/or clinically significant drug-drug interactions related
to the tested transporters is considerably lower than that of adefovir, tenofovir, and
cidofovir.
Keywords: antivirals, nephrotoxicity, renal disposition, drug–drug interactions
INTRODUCTION
Entecavir (ETV), a synthetic guanosine analog, is one of the most potent and highly selective
agents for the treatment of chronic hepatitis B (HBV) infection. The active 5′-triphosphate of
ETV inhibits the replication of HBV at all three steps of the synthesis process (Scott and Keating,
2009). ETV is eliminated primarily in the urine by glomerular ﬁltration and tubular secretion
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FIGURE 1 | Time-dependent uptake of typical substrates in transiently transfected cell models and demonstration of overexpression of transporters
in transfected cells using Western blot analysis. The time profile of the uptake of 1 μM [3H]PAH via hOAT1 (filled circles) and empty vector (pCMV6) transfected
(open squares) HeLa cells (A). The time profile of the uptake of 1 μM [3H]MPP+ via hOCT2 (filled circles) and empty vector transfected (open squares) MDCK II cells
(B). The time profile of the uptake of 1 μM [3H]uridine via hCNT2 (filled circles) and empty vector transfected (open squares) MDCK II cells (C). The time profile of the
uptake of 1 μM [3H]uridine via hCNT3 (filled circles) and empty vector transfected (open squares) MDCK II cells (D). Experiments were performed in triplicates.
Western blot analysis: overexpression of the appropriate transporter (lane 2) or negative control (empty vector transfected cells, lane 1) in cell lysates.
(Matthews, 2006; Razonable, 2011). For various purposes ETV
may be combined in therapy with various antivirals or other
drugs. Recently, combinations of ETV and other anti-HBV drugs
such as adefovir or tenofovir have been demonstrated to be
eﬀective in patients with some types of resistance to antiviral
therapy (Sheng et al., 2011; Chae et al., 2012).
The solute carrier family (SLC) of membrane transporters
located in the renal proximal tubular cells have been shown
to interact with numerous widely used antivirals (Cihlar et al.,
2009; Minuesa et al., 2011). Transport systems for organic anions
(OATs) and cations (OCTs) have been found to transport a
variety of compounds in kidney cells (Koepsell and Endou, 2004;
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FIGURE 2 | Effect of ETV on the accumulation of typical substrates of the studied transporters. The HeLa cells transiently transfected with the expressing
vector for hOAT1 (A) and MDCK II cells transiently transfected with the expressing vector for hOCT2 (B), hCNT2 (C), hCNT3 (D) were incubated with 1 μM [3H]PAH
(A), 1 μM [3H]MPP+ (B) and 1 μM [3H]uridine (C,D) in the presence of gradually increasing concentrations of ETV (0–2000 μM) for 2 min at 37◦C in triplicates. Each
point represents the mean ± SD of the accumulated amounts of radiotracer. The IC50 value represents the inhibitory concentration of ETV calculated using
non-linear regression analysis. The value of radiotracer accumulation in the cells transfected with empty vector was subtracted.
El-Sheikh et al., 2008). The most abundantly expressed types
of OATs and OCTs in human renal tubular cells are human
organic anion transporter 1 (hOAT1) and human organic cation
transporter 2 (hOCT2), respectively (Klaassen and Aleksunes,
2010). Several guanosine antivirals show substrate speciﬁcity
to the OAT and OCT families (Minuesa et al., 2011). For
example, antiviral agents from the group of acyclic nucleoside
phosphonates such as adefovir, tenofovir, and cidofovir have
been characterized as substrates of hOATs (Uwai et al.,
2007).
The possible involvement of OATs and OCTs in the renal
excretion of ETV has been suggested in rats in vivo (Yanxiao et al.,
2011). Recently, OAT1, OAT3 and OCTs have been described
to transport ETV in genetically engineered cell lines and kidney
slices (Xu et al., 2013).
Concentrative nucleoside transporters (SLC28A1-3; CNTs)
may also play an important role in the transmembrane
transport of synthetic nucleoside analogs into various cells (Gray
et al., 2004; Errasti-Murugarren et al., 2010). CNTs mediate
the unidirectional uptake of nucleosides in an active process
(Molina-Arcas and Pastor-Anglada, 2010). The types 1 (hCNT1),
2 (hCNT2), and 3 (hCNT3) are typically expressed in the
proximal tubular cells of human kidney (Mangravite et al., 2003;
Klaassen and Aleksunes, 2010). CNT1 and CNT2 are pyrimidine
nucleoside-preferring and purine nucleoside-preferring carriers,
respectively, whereas CNT3 shows broader substrate selectivity
(Gray et al., 2004). Interestingly, ribavirin, a guanosine analog
antiviral agent, has been detected as a high-aﬃnity substrate of
hCNT2 and hCNT3 (Yamamoto et al., 2006; Cano-Soldado and
Pastor-Anglada, 2012). However, interaction of ETVwith hCNT2
and hCNT3 has not been studied so far.
In the current study we hypothesized that human renal
drug inﬂux transporters, including hOAT1, hOCT2, hCNT2
and hCNT3, might be involved in the handling of ETV in
the renal tubules. These transporters could be potential sites
for the interaction of ETV with other antiviral drugs such as
tenofovir, adefovir, and cidofovir transported by the same renal
transport systems. Importantly, interactions with the selected
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FIGURE 3 | The time-dependent profile of [3H]ETV uptake. The time profile of the uptake of 0.1 μM [3H]ETV in hOAT1 (A), hCNT2 (B), hCNT3 (C) and hOCT2
(D) transiently transfected cells (filled circles) or empty vector (pCMV6) transfected cells (open squares) at 37◦C in triplicates. The uptake was linear within first 5 min
of incubation. Each point represents the mean ± SD of the accumulated amount of [3H]ETV.
transporters could result in nephrotoxicity caused by transport-
related accumulation.
Along these lines of inquiry, the aim of this study was to
investigate the interactions of ETV with the selected renal SLC
transporters in vitro using genetically engineered cell models.
We also analyzed potential drug-drug interactions of ETV with
adefovir, tenofovir, and cidofovir. Finally, we compared the
cytotoxicity of the tested antivirals and assessed the signiﬁcance
of OAT1 transporter for in vitro toxic eﬀects of ETV and
comparators.
MATERIALS AND METHODS
Chemical Reagents Used
Entecavir, adefovir, and tenofovir were obtained from Santa
Cruz Biotechnology (Paso Robles, CA, USA). Cidofovir
was purchased from Sigma Aldrich (St. Louis, MO, USA).
[Adenine-2,8-3H]-adefovir ([3H]adefovir), [adenine-2,8-3H]-
tenofovir ([3H]tenofovir), [5-3H]-cidofovir ([3H]cidofovir)
and [5-3H]-uridine ([3H]uridine) were obtained from
Moravek Biochemicals (Brea, CA, USA). The p-[glycyl-
2-3H]-aminohippuric acid ([3H]PAH) was purchased
from Perkin Elmer (Waltham, MA, USA). Radiolabeled
ETV ([3H]ETV) and methyl-4-phenylpyridinium acetate
([3H]MPP+) were obtained from American Radiolabeled
Chemicals (St. Louis, MO, USA). Expression plasmids
were obtained from OriGene Technologies (Rockville, MD,
USA).
Cell Culturing
The human cervical epithelioid carcinoma cell line (HeLa)
and Madin–Darby canine kidney cell line (MDCK II) were
purchased from the European Collection of Cell Culture
(Salisbury, UK). The HeLa cells were routinely cultured in
Eagles minimum essential medium (EMEM). The MDCKII
were routinely cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM).
Transfection
The HeLa cells were seeded at a density of 7 × 104 cells
per well in 24-well plates. The MDCK II cells were seeded
at a density of 2 × 105 cells per well in 24-well plates. In
cytotoxicity assays, the HeLa cells were seeded at a density
of 15 × 103 cells per well. The following day the cells were
transiently transfected with appropriate plasmid coding for the
studied transporter or empty vector pCMV6-Entry (pCMV6,
empty vector) using the Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA) and Opti-MEM (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol. The cells
transiently transfected with the appropriate empty vector served
as a control. The overexpression of the studied transporters
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FIGURE 4 | Concentration-dependent uptake of [3H]ETV. The uptake of
[3H]ETV in hOAT1 (A), hCNT2 (B), and hCNT3 (C) transiently transfected cells
was measured at different concentrations after 5 min of incubation at 37◦C in
triplicates. Each point represents the mean ± SD of the accumulated amount
of [3H]ETV. The value of radiotracer accumulation in the cells transfected with
empty vector was subtracted.
was checked by Western blot analysis and by function tests
using an accumulation study with tritium-labeled prototypical
substrates.
Interactions with SLC Transporters
Inhibitory transport assays were carried out in 24-well plates
as described previously (Mandikova et al., 2013). Transport
assays in HeLa cells transiently transfected with the hOAT1
expression construct were performed 48 h after transfection.
Transport assays in MDCK II cells transiently transfected
with hOCT2, hCNT2 or hCNT3 were performed 24 h after
transfection. The cultivation medium was removed and the
cells were washed with transport solution and preincubated
for 10 min at 37◦C. The standard radiolabeled substrate or
tested radioactive antiviral substance dissolved in transport
solution was added to the cells and incubated for 2 min.
[3H]PAH (1 μM) was used as a prototypical substrate for
OATs, [3H]MPP+ (1 μM) for OCTs and [3H]uridine (1 μM)
for CNTs. The rate of inhibition of intracellular accumulation
of the radioactive substrates induced by gradually increasing
concentrations of ETV (0–2000 μM) was used as a measure
of the inhibitory eﬀect on the transporter. [3H]adefovir
(0.1 μM), [3H]tenofovir (0.5 μM) and [3H]cidofovir (70 μM)
were used in the interaction experiments with ETV. After
the designated time period, the incubation was stopped by
washing the cells twice with ice-cold solution containing
137 mM NaCl and 10 mM HEPES, pH 7.4. The cells were
disintegrated with 0.1 mL of Triton X 0.5% in 100 mM NaOH
for 1 h.
To test if the ETV was a substrate of the tested inﬂux
transporters, the accumulation of [3H]ETV was studied in
hOAT1, hOCT2, hCNT2 and hCNT3 transfected cells during a
5min period. To determine the kinetic parameters,Km andVmax,
[3H]ETV in increasing concentrations (0–500 μM) in triplicates
was incubated for 5 min with the cells transfected by hOAT1,
hCNT2 or hCNT3.
The results regarding inhibition were expressed as the
concentration of inhibitor IC50, which resulted in the
half-rate inhibition of transport of the labeled substrate.
IC50 values were calculated using non-linear regression
analysis using GraphPad Prism software (version 6). The
kinetic parameters Km and Vmax for the uptake of ETV
was derived from a non-linear regression analysis of the
Michaelis–Menten model using GraphPad Prism software
(version 6).
Cytotoxicity Assays
The Hela cells were plated in a 96-well plate and transfected
with hOAT1 as described above. After transfection, the cells
were treated with ETV, adefovir, tenofovir, or cidofovir at
concentrations 50–1000 μM in triplicates. To determine
potential ETV cytotoxicity mediated by hCNT2 or hCNT3, the
MDCK II cells were plated in a 96-well plate, transfected
with hCNT2 or hCNT3a, and treated with ETV at
concentrations 250–1000 μM. The controls were prepared
simultaneously. After 24 h of incubation, the reagent from
the kit CellTiter 96 AQueous One Solution Cell Proliferation
Frontiers in Pharmacology | www.frontiersin.org 5 January 2016 | Volume 6 | Article 304
Mandíková et al. Entecavir Interactions with Renal Transporters
FIGURE 5 | Comparison of the inhibitory effect of adefovir, tenofovir, and cidofovir on hCNT2 and hCNT3. The MDCK II cells transiently transfected with
the expressing vector for hCNT2 (A) and hCNT3 (B) were incubated with 1 μM [3H]uridine in gradually increasing concentrations of adefovir, tenofovir, and cidofovir
(0–1000 μM) for 2 min at 37◦C in triplicates. Each point represents the mean ± SD of the accumulated amounts of 1 μM [3H]uridine. The value of radiotracer
accumulation in the cells transfected with empty vector was subtracted.
Assay (CellTiter 96, PROMEGA, USA) was added. After
1.5 h of incubation at 37◦C the absorbance was recorded at
490 nm.
Western Blot Analysis
The HeLa cells and the MDCK II cells were transiently
transfected with the transporters of interest as described above.
As negative control cells, transiently transfected with empty
vector were used. After protein separation and transmission
to polyvinylidene membrane (Sigma–Aldrich, St. Louis, MO,
USA), the membrane was incubated with anti-SLC22A6
(AB1), anti-SLC28A2, anti-SLC28A3 (Sigma–Aldrich, St.
Louis, MO, USA), anti-SLC22A2 (Abcam, Cambridge, UK)
or anti-β-actin antibody (Sigma–Aldrich, St. Louis, MO,
USA). β -actin was used as a loading control. Detection
was performed with appropriate peroxidase-conjugated
secondary antibodies (GE Healthcare, Little Chalfont, UK;
Sigma–Aldrich, St. Louis, MO, USA). The immunoreactive
bands on the X-ray ﬁlm (FOMA Bohemia, Hradec Kralove,
Czech Republic) were scanned with the calibrated CCD
camera Image Quant 400 (GE Healthcare, Little Chalfont,
UK).
Statistical Analysis
Data obtained in the experiments are expressed as mean ± SD.
All experiments were performed in triplicates. The statistical
signiﬁcance of the diﬀerence in the parameters was determined
using a two-way ANOVA test (interaction with SLC transporters)
in GraphPad Prism software (version 6). Diﬀerences were
considered signiﬁcant at p-value<0.05.
RESULTS
Validation of the Transport Studies
To check the validity of the transport studies, the time proﬁle of
the uptake of each of the [3H]-labeled standard substrates in the
appropriate transfected cell line was determined (Figure 1). The
intracellular accumulation of [3H]PAH (Figure 1A), [3H]MPP+
(Figure 1B) and [3H]uridine (Figures 1C,D) in the cells
transfected with the appropriate transporter was linear within
5 min, and it was also markedly higher in the cells transfected
with the transporter of interest than in the cells transfected with
the empty vector. Using an interval of 2 min of incubation it was
demonstrated that the uptake of all typical substrates tested in
the appropriate cell model was at least 13-fold higher than in the
control cells transfected with empty vector.
Evaluation of Transfection Effectiveness
by Western Blotting
To conﬁrm the expression of the tested SLC transporters
after transient transfection, a Western blot analysis of protein
extracts from the cells transfected with studied transporters was
performed. As the controls, HeLa and MDCK II cells transfected
with the empty vector were used. A signiﬁcant increase in the
level of the tested transporters was demonstrated in comparison
with the cells transfected with empty vector (Figure 1).
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FIGURE 6 | Effect of ETV on adefovir, tenofovir, and cidofovir
accumulation mediated by OAT1 in HeLa cells. The accumulation of
[3H]adefovir (0.1 μM) (A), [3H]tenofovir (0.5 μM) (B) and [3H]cidofovir (70 μM)
(C) was inhibited by ETV (0–1000 μM) for a 2 min period in HeLa cells
transiently transfected with hOAT1. Each point represents the mean ± SD of
the accumulated amounts of radiotracer. The IC50 value represents the
inhibitory concentration of ETV calculated using non-linear regression analysis.
The value of radiotracer accumulation in the cells transfected with empty
vector was subtracted.
Interactions of Entecavir and
Comparators with SLC Transporters
Inhibitory Effect of ETV on Transporters
To prove whether ETV is an inhibitor of the tested SLC
transporters, the cell line transiently transfected by hOAT1,
hOCT2, hCNT2 or hCNT3 were incubated with [3H]-labeled
typical substrates in combination with unlabeled ETV. An
evaluation of the potential to inhibit accumulation of the
standard substrates in the cell models revealed a considerable
eﬀect of ETV on hOAT1, hCNT2 and hCNT3 mediated
transport, with IC50 being 175.3; 241.9, and 278.4 μM,
respectively (Figure 2). No interaction of ETV with hOCT2 was
observed under the used conditions (Figure 2).
ETV Influx by Transporters
In order to determine whether ETV is a substrate of the
tested transporters, a set of uptake transport studies with
[3H]ETV in the cells transfected by hOAT1, hOCT2, hCNT2
and hCNT3 was carried out (Figure 3). In time dependent
studies, the uptake of [3H]ETV was linear in the ﬁrst 5 min.
The uptake of [3H]ETV in the hOAT1, hCNT2 and hCNT3
transfected cells was signiﬁcantly higher than in the empty vector
(pCMV6) transfected control cells (Figures 3A–C). ETV was
found to be a substrate of hOAT1, hCNT2 and hCNT3. The
appropriate kinetic parameters are presented in Figure 4. The
transport eﬃciency (Vmax/Km) values (μl/5 min/mg) for hOAT1,
hCNT2 and hCNT3 were 2.88, 45.2 and 462.9, respectively. In
contrast, we did not ﬁnd any interaction of ETV with hOCT2
(Figure 3D).
Comparative Study and Interactions with Selected
Antivirals
The results of a comparative study on the inhibitory eﬀect
of adefovir, tenofovir, and cidofovir on hCNT2 and hCNT3
are presented in Figure 5. Interactions of adefovir, tenofovir,
and cidofovir with hOAT1 have been shown previously
(Mandikova et al., 2013). Signiﬁcant interactions of adefovir,
tenofovir, and cidofovir with hCNT2 (Figure 5A) and hCNT3
(Figure 5B) were not observed. To evaluate the potential
interactions of ETV with the other studied antivirals at
hOAT1, the accumulation of [3H]-labeled adefovir, tenofovir,
and cidofovir was studied in HeLa cells transfected with
hOAT1 in combination with increasing concentrations of ETV.
The results demonstrated a considerable inhibition of the
uptake of all the tested antivirals by ETV in the model cells
(Figure 6).
Effect of OAT1, CNT2 and CNT3 on
Cytotoxicity of Entecavir
To measure the relation between the eﬀect of the tested
agents on cell viability and ability to interact with hOAT1, a
standard MTS colorimetric cell viability assay was performed
using hOAT1 transfected cells. As shown in Figure 7A, the
treatment of ETV at the concentrations tested (250, 500, and
1000 μM) had no signiﬁcant eﬀect on cell viability in hOAT1
transfected cells in comparison with the control cells. The high
expression of hOAT1 signiﬁcantly enhanced the cytotoxic eﬀect
of adefovir, tenofovir, and cidofovir in comparison with the
empty vector transfected cells (Figures 7B–D). The study in cells
overexpressing hCNT2 or hCNT3 did not prove any signiﬁcant
increase in cytotoxicity in the transfected cells in comparison
with the controls (Figure 8).
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FIGURE 7 | Effect of hOAT1 expression on cytotoxicity of the tested antiviral drugs. HeLa cells transiently transfected with hOAT1 (open circles) and empty
vector pCMV6 (closed squares) were incubated for 24 h with three various concentrations of ETV (A), adefovir (B), tenofovir (C) and cidofovir (D). The experiments
were carried out simultaneously with hOAT1 and empty vector transfected cells in triplicates. Data are presented as means ± SD. The values from the end point
were subjected to statistical analysis. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 compared with control.
DISCUSSION
To study the role of the individual transporters contributing
to ETV renal handling, we selected the main types of drug
transporters abundantly expressed in human kidney which
might be potentially involved in ETV transmembrane transport.
This work builds on an in vivo study which suggested an
involvement of organic anion and cation transporters in the
renal excretion of ETV (Yanxiao et al., 2011). The authors
of this study have demonstrated that both probenecid and
cimetidine show an inhibitory eﬀect on the renal excretion
of ETV after intravenous coadministration. Probenecid is a
commonly used potent inhibitor of OATs (Cihlar et al., 1999;
Burckhardt and Burckhardt, 2003). Thus our results support
the above-mentioned data found in vivo and conﬁrm ETV
interaction with the human renal inﬂux transporter for organic
anions hOAT1. The found data conﬁrmed the ﬁndings by
Xu et al. (2013) who demonstrated interactions of ETV with
hOATs using a similar in vitro cellular model. The value of
Km = 316.5 μM found for hOAT1 is in accordance with the
previously published value of 250 μM (Xu et al., 2013). In
contrast to the ﬁndings in rats in vivo (Yanxiao et al., 2011)
and in an in vitro study using rat renal slices (Xu et al., 2013)
suggesting the participation of OCTs in the transport of ETV, we
did not prove any interaction of ETV with hOCT2 in the used
in vitro cell model (Figure 3D). A relevant explanation for these
contradictory ﬁndings may be a possible contribution of other
subtypes of OCTs to renal transport in vivo and in the rat renal
slices. Since we employed the model of human OCT2, another
explanation may be interspecies diﬀerences in ETV aﬃnity to
OCTs, as the other studies mentioned used rat experimental
models.
Our experiments enabled the direct comparison of the
ability of the tested antivirals to interact with hOAT1 in one
experimental model. The investigation showed that the potential
of ETV to inhibit the transport of [3H]PAH into transfected cells
seems to be considerably lower than that of adefovir, tenofovir,
and cidofovir (Mandikova et al., 2013). The tested antiviral agents
can be arranged according to the inhibitory eﬀect on hOAT1 in
the following descending order: adefovir> tenofovir ≈ cidofovir
>> ETV. Based on the proved potency of ETV to inhibit
hOAT1, experiments focusing on the drug–drug interactions of
ETV with three known substrates of hOATs, adefovir, tenofovir,
and cidofovir (Cihlar et al., 1999; Uwai et al., 2007) were
performed. We used concentrations of adefovir (0.1 μM),
tenofovir (0.5 μM) and cidofovir (70 μM), which correspond
to therapeutic plasma levels achieved in humans (Cundy, 1999;
Kearney et al., 2005; Delahunty et al., 2006). We demonstrated
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FIGURE 8 | Effect of hCNT2 and hCNT3 expression on cytotoxicity of
ETV. MDCK II cells transiently transfected with hCNT2 or CNT3 (closed
circles) or empty vector pCMV6 (open squares) were incubated for 24 h with
three various concentrations of ETV. The experiments were carried out
simultaneously with hCNT2 (A) or hCNT3 (B) and empty vector transfected
cells in triplicates. Data are presented as means ± SD. The values from the
end point were subjected to statistical analysis. ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p < 0.001 compared with control.
the considerable potency of ETV to inhibit transport by hOAT1
in all three antiviral agents in high micromolar concentrations
(Figure 6). Still, the therapeutic concentrations of ETV in
plasma following regular doses have been declared to be at
below 50 nM (Matthews, 2006; Yan et al., 2006). Therefore the
clinical signiﬁcance of these drug-drug interactions at hOAT1
could be expected only in case of high plasma concentrations of
ETV caused by overdosing or intoxication. Our ﬁnding support
several clinical studies that reported that ETV and adefovir
or tenofovir can be administrated together without the risk of
pharmacokinetic interaction (Bifano et al., 2007; Jiménez-Pérez
et al., 2010).
CNT carriers are responsible for the high-aﬃnity
concentrative reabsorption of natural nucleosides and their
analogs in the kidney (Ritzel et al., 2001; Rodríguez-Mulero
et al., 2005); CNT2 mediates the uptake of antiviral purine
derivatives such as cladribine, ﬂudarabine, and clofarabine (Lang
et al., 2001; King et al., 2006; Cano-Soldado and Pastor-Anglada,
2012). Thus, we hypothesized the same eﬀect for ETV and
our aim was to clarify for the ﬁrst time the interactions of
ETV with nucleoside transporters hCNT2 and hCNT3. Our
ﬁndings indicate that the interaction of ETV with these two
CNTs expressed in the kidney (Mangravite et al., 2003; Klaassen
and Aleksunes, 2010) could be signiﬁcant in terms of the renal
handling of ETV (Figure 3). Because the CNTs are located at
the apical membrane of the renal tubular cells (Mangravite et al.,
2003) they may mediate reabsorption of ETV from the urine.
Although CNT2 and CNT3 mRNA expression in the human
kidney is several times lower than that of hOAT1 (Nishimura
and Naito, 2005), the diﬀerent cellular location may lead to
diﬀerent exposure to the drug. If we consider that about 70% of
ETV dose is excreted via the urine (Matthews, 2006), the reached
concentration in the ﬁnal urine following administration of 1 mg
could be in case of 24 h-urinary volume of 1 L approximately
700 μg/L (2.5 μM). Such concentration would be relatively high
in comparison with that in plasma but not reaching the found
Km of ETV for hCNT2 and hCNT3. However, CNTs are located
in the proximal tubules (Klaassen and Aleksunes, 2010) where
drug concentration in the ultraﬁltrate is close to that in the
plasma. Since ETV concentration is rising along the proximal
tubules continually due to obligatory ﬂuid reabsorption it is
diﬃcult to assess if the eﬀective transport concentrations might
be reached in vivo. Because secretion of ETV is the predominant
process in the kidney, the tested hCNT transporters probably
do not play under standard situations a quantitatively important
role in ETV renal transport. In contrast to ETV, none of the
tested antivirals (adefovir, cidofovir, and tenofovir) interacted
with hCNT2 or with hCNT3 in the transiently transfected
MDCK II cells (Figure 5). Therefore, no interactions involving
CNT2 or CNT3 between ETV and these antivirals can be
expected.
The accumulation of drugs in the cells mediated by inﬂux
transporters may be responsible for the resulting cytoxicity. In
Ho et al. (2000) documented a critical role of OAT1 in the
cytotoxic eﬀect of adefovir and cidofovir in vitro using a cellular
model. Adefovir, cidofovir, and tenofovir have been proved to
possess a signiﬁcant nephrotoxic potential in treated patients
(Izzedine et al., 2005). Since OAT1 is typically abundantly
expressed in the kidney (Klaassen and Aleksunes, 2010), the
toxic potency of these drugs may be at least partly related
to this transporter. In experiments aimed at OAT1-mediated
cytotoxicity we found a markedly lower aﬃnity of ETV to OAT1
and a lower cytotoxic eﬀect of ETV in the cells transfected with
hOAT1 in comparison with the above-mentioned nephrotoxic
antivirals. Therefore, a lower risk of cellular accumulation
may be expected for ETV than with adefovir, tenofovir, and
cidofovir in tissues with a high expression of OAT1. In the
publication by Ho et al. (2000), the authors determined Km
of adefovir 23.8 μM and Km of cidofovir 58.0 μM in CHO
cells stably expressing hOAT1. After 5 days of incubation
with the tested antiviral drugs, the authors performed MTT
cytotoxicity assay showing higher cytotoxic potential of adefovir
than cidofovir. In our experiments in HeLa cells transiently
transfected with hOAT1 we found Km of ETV 316.5 μM
suggesting lower uptake of ETV by hOAT1 and thus lower
potential for cytotoxicity in comparison with adefovir and
cidofovir. In accordance with this, our results from the study
on hOAT1-mediated cytotoxicity measured by MTS method
in HeLa cells after 24 h of incubation indicate that the least
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cytotoxic antiviral drug was ETV followed by cidofovir and
adefovir. The diﬀerences between the cytotoxicity of antiviral
drugs presented in these two papers may stem from diﬀerent
incubation times of antiviral drugs with the hOAT1 expressing
cells (in Ho’s paper 5 days, in our study 1 day), type of cells and the
method of transfection, but the general order of the cytotoxicity
of the tested antivirals seems to be the same in both studies.
Because of the found signiﬁcant interaction of ETV with hCNTs,
we also tested potential transporter-mediated cytotoxicity related
to the hCNT2 or hCNT3. Similar results were obtained because
any sign of the transporter-mediated toxicity was not detected.
Therefore, the cytotoxicity of ETV dependent on these two
transporters seems to be also not probable. Our results on lacking
cytotoxicity of ETV are in accordance with previously published
data that demonstrated, that ETV is a safe and generally well
tolerated drug used in patients with chronic HBV infection
(Liaw et al., 2011). Nevertheless, prolonged administration of a
nucleoside analog to any patient may enhance the risk of toxic
reactions, especially in patients with impaired renal or hepatic
function (Scott and Keating, 2009).
CONCLUSION
Based on our data we suppose that the risk of ETV nephrotoxic
eﬀect caused by accumulation via the tested transporters is
unlikely under standard therapeutic conditions. The presented
study conﬁrms in vitro a potency of high ETV concentrations to
compete with adefovir, tenofovir, and cidofovir at the transporter
hOAT1. We also for the ﬁrst time demonstrate that ETV
is an inhibitor and substrate of CNTs. However, the found
ETV interactions with the studied transporters are likely to
be manifested in the kidney only under the special conditions
associated with high levels of ETV, such as absolute or relative
overdosing.
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